Latest Research & Breakthroughs
Curated cancer research, clinical trial results, and guideline updates — filtered for relevance to integrative and evidence-based oncology.
For Informational Purposes Only
Content on this page is for educational purposes only and does not constitute medical advice.
Curcumin Combined with Chemotherapy Shows Synergistic Effects in Breast Cancer Trial
Journal of Clinical Oncology
A Phase II randomised controlled trial published in the Journal of Clinical Oncology found that curcumin supplementation (2g daily) significantly enhanced the response rate to neoadjuvant chemotherapy in triple-negative breast cancer patients, with a 68% pathological complete response rate compared to 42% in the control group. The curcumin group also reported lower rates of nausea and peripheral neuropathy.
Read Full ArticleMistletoe Therapy Approved in Swiss National Oncology Guidelines as Evidence-Based Adjuvant
Swiss Cancer Bulletin
Switzerland's National Cancer Institute has updated its integrative oncology guidelines to formally recommend mistletoe (Viscum album) as an adjuvant therapy for patients undergoing conventional cancer treatment. The recommendation is based on a systematic review of 41 clinical trials showing consistent benefits for quality of life, fatigue reduction, and immune function improvement with a strong safety record.
Read Full ArticleKetogenic Diet Shown to Enhance Immunotherapy Response in Non-Small Cell Lung Cancer
Cancer Research
Researchers at MD Anderson Cancer Centre published a prospective study showing that patients with non-small cell lung cancer who followed a ketogenic diet during PD-1 inhibitor immunotherapy had significantly better progression-free survival (11.2 months vs 6.8 months) compared to standard diet controls. The researchers propose that ketosis alters the tumour microenvironment to favour immune cell infiltration.
Read Full ArticleTurkey Tail Mushroom Polysaccharides Shown to Restore Immune Function After Chemotherapy
ISRN Oncology
A double-blind placebo-controlled study from Bastyr University Research Institute found that breast cancer survivors who took 6 grams of Turkey Tail mushroom (Trametes versicolor) daily for three months had significantly greater NK cell proliferative response and higher CD8+ T-cell counts compared to placebo, suggesting clinically meaningful immune restoration following conventional chemotherapy.
Read Full ArticleModified Citrus Pectin Reduces Circulating Tumour Cells in Prostate Cancer: Phase II Results
Frontiers in Oncology
A Phase II trial published in Frontiers in Oncology demonstrated that modified citrus pectin (15g/day) significantly reduced circulating tumour cell counts in men with castration-resistant prostate cancer over 6 months. Secondary endpoints showed PSA stabilisation and improved quality of life scores. The authors propose galectin-3 inhibition as the primary mechanism.
Read Full ArticleWHO Report: Integrative Cancer Care Adoption Rising Globally, 40% of Patients Now Using Complementary Therapies
World Health Organization
A new WHO report on global cancer care trends reveals that 40% of cancer patients worldwide now use some form of complementary or integrative therapy alongside conventional treatment. The report calls for greater integration of evidence-based complementary approaches into national cancer programmes and emphasises the need for standardised training for oncologists in discussing these therapies with patients.
Read Full ArticleFasting Before Chemotherapy Reduces Side Effects Without Compromising Efficacy, Meta-Analysis Confirms
The Lancet Oncology
A comprehensive meta-analysis of 14 randomised clinical trials involving 1,200 cancer patients confirms that short-term fasting (24–72 hours) before chemotherapy significantly reduces nausea, fatigue, DNA damage in normal cells, and haematological toxicity without reducing chemotherapy efficacy. The analysis supports differential stress resistance — cancer cells cannot adapt to fasting while normal cells can.
Read Full ArticleAshwagandha Significantly Reduces Cancer-Related Fatigue in Randomised Trial
Journal of Integrative Cancer Therapies
A randomised double-blind placebo-controlled trial published in the Journal of Integrative Cancer Therapies found that ashwagandha root extract (KSM-66, 300 mg twice daily) significantly reduced cancer-related fatigue scores by 57% over 8 weeks in patients undergoing chemotherapy, compared to 8% improvement in the placebo group. Secondary outcomes including sleep quality, anxiety, and cortisol levels all improved significantly in the ashwagandha group.
Read Full ArticleHow we select these articles
Articles are curated for relevance to integrative oncology, repurposed drugs, and lifestyle interventions. All summaries are paraphrased from the original source — always follow the link to read the full study before making any health decisions.